company background image
A326

SK Biopharmaceuticals KOSE:A326030 Stock Report

Last Price

₩86.60k

Market Cap

₩6.8t

7D

-2.1%

1Y

-23.0%

Updated

23 May, 2022

Data

Company Financials +
A326030 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends0/6

A326030 Stock Overview

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders.

SK Biopharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for SK Biopharmaceuticals
Historical stock prices
Current Share Price₩86,600.00
52 Week High₩137,500.00
52 Week Low₩73,000.00
Beta0
1 Month Change-0.23%
3 Month Change9.07%
1 Year Change-23.02%
3 Year Changen/a
5 Year Changen/a
Change since IPO-31.81%

Recent News & Updates

Shareholder Returns

A326030KR PharmaceuticalsKR Market
7D-2.1%0.8%1.6%
1Y-23.0%-26.6%-14.2%

Return vs Industry: A326030 exceeded the KR Pharmaceuticals industry which returned -26.6% over the past year.

Return vs Market: A326030 underperformed the KR Market which returned -14.2% over the past year.

Price Volatility

Is A326030's price volatile compared to industry and market?
A326030 volatility
A326030 Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement4.4%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market3.2%

Stable Share Price: A326030 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A326030's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/aJeong Woo Chohttps://www.skbp.com

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy.

SK Biopharmaceuticals Fundamentals Summary

How do SK Biopharmaceuticals's earnings and revenue compare to its market cap?
A326030 fundamental statistics
Market Cap₩6.78t
Earnings (TTM)₩64.85b
Revenue (TTM)₩418.64b

104.6x

P/E Ratio

16.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A326030 income statement (TTM)
Revenue₩418.64b
Cost of Revenue₩22.34b
Gross Profit₩396.31b
Other Expenses₩331.46b
Earnings₩64.85b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)828.03
Gross Margin94.66%
Net Profit Margin15.49%
Debt/Equity Ratio0%

How did A326030 perform over the long term?

See historical performance and comparison

Valuation

Is SK Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


104.59x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A326030's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A326030's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: A326030 is poor value based on its PE Ratio (104.6x) compared to the KR Pharmaceuticals industry average (25.6x).

PE vs Market: A326030 is poor value based on its PE Ratio (104.6x) compared to the KR market (14x).


Price to Earnings Growth Ratio

PEG Ratio: A326030 is poor value based on its PEG Ratio (5x)


Price to Book Ratio

PB vs Industry: A326030 is overvalued based on its PB Ratio (15.3x) compared to the KR Pharmaceuticals industry average (1.6x).


Future Growth

How is SK Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A326030's forecast earnings growth (20.8% per year) is above the savings rate (3.5%).

Earnings vs Market: A326030's earnings (20.8% per year) are forecast to grow faster than the KR market (14.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A326030's revenue (11.5% per year) is forecast to grow faster than the KR market (9.7% per year).

High Growth Revenue: A326030's revenue (11.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A326030's Return on Equity is forecast to be low in 3 years time (13.1%).


Past Performance

How has SK Biopharmaceuticals performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


1,510.2%

Last years revenue growth

Earnings and Revenue History

Quality Earnings: A326030 has a large one-off gain of ₩51.5B impacting its December 31 2021 financial results.

Growing Profit Margin: A326030 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A326030's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A326030's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: A326030 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.9%).


Return on Equity

High ROE: A326030's Return on Equity (14.6%) is considered low.


Financial Health

How is SK Biopharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A326030's short term assets (₩471.2B) exceed its short term liabilities (₩148.3B).

Long Term Liabilities: A326030's short term assets (₩471.2B) exceed its long term liabilities (₩51.2B).


Debt to Equity History and Analysis

Debt Level: A326030 is debt free.

Reducing Debt: A326030 had no debt 5 years ago.

Debt Coverage: A326030 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: A326030 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is SK Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A326030's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A326030's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A326030's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A326030's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A326030 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average board tenure


CEO

Jeong Woo Cho

5.33yrs

Tenure

Mr. Jeong Woo Cho, PhD, serves as Director at SK Biopharmaceuticals Co., Ltd. since March 16, 2017. He is the President & CEO at SK Biopharmaceuticals Co., Ltd and SK Life Science, Inc. since 2017.Mr. Cho...


Board Members

Experienced Board: A326030's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

SK Biopharmaceuticals Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: SK Biopharmaceuticals Co., Ltd.
  • Ticker: A326030
  • Exchange: KOSE
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩6.782t
  • Shares outstanding: 78.31m
  • Website: https://www.skbp.com

Location

  • SK Biopharmaceuticals Co., Ltd.
  • 221, Pangyoyeok-ro
  • Bundang-gu
  • Seongnam-si
  • Gyeonggi-do
  • 13494
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.